Predicting antibody penetration in a first-in-human clinical trial of head and neck cancers (Conference Presentation)

2019 ◽  
Author(s):  
Guolan Lu ◽  
Shayan Fakurnejad ◽  
Brock Martin ◽  
Ashley Zhu ◽  
Nynke van den Berg ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Head And Neck ◽  
Head And Neck Cancers ◽  
Human Clinical Trial

Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review

2015 ◽  
Vol 129 (11) ◽  
pp. 1046-1052 ◽  
Author(s):  
B Cosway ◽  
V Paleri ◽  
J Wilson
Keyword(s):  
Clinical Trial ◽  
Head And Neck ◽  
Evidence Base ◽  
Chemotherapeutic Agents ◽  
Head And Neck Cancers ◽  
Future Research ◽  
Chemotherapy Response ◽  
Oncological Treatment ◽  
Pubmed Database ◽  
Response To Chemotherapy

AbstractBackground:Biomarkers are increasingly being used in many cancers to select patients for oncological treatment paradigms based on their inherent genetic properties. However, in head and neck cancers, there are no personalised therapies available outside the context of a clinical trial. A number of studies suggest there are intrinsic tumour properties of head and neck cancers that affect their response to chemotherapeutic agents. This paper aimed to review their evidence base.Method:A narrative review was conducted following a search of the PubMed database.Results and conclusion:The review identified a number of biomarkers predicting response to chemotherapy in head and neck cancers. The paper discusses these in detail, and explores where future research could be directed in order to deliver personalised therapies for patients with head and neck cancers.

The Epidemic of HPV-Associated Oropharyngeal Cancer Is Here: Is It Time to Change Our Treatment Paradigms?

2011 ◽  
Vol 9 (6) ◽  
pp. 665-673 ◽  
Author(s):  
Erich M. Sturgis ◽  
K. Kian Ang
Keyword(s):  
Clinical Trial ◽  
Human Papillomavirus ◽  
Head And Neck ◽  
Oropharyngeal Cancer ◽  
Head And Neck Cancers ◽  
Population Changes ◽  
Clinical Behavior ◽  
Incidence Trends

Although relatively uncommon, oropharyngeal cancers are increasing in incidence despite declining prevalence of smoking and in direct opposition to a decreasing incidence of all other head and neck cancers. An epidemic of human papillomavirus (HPV)–associated oropharyngeal cancers seems to account for these incidence trends. Important demographic, behavioral, and prognostic characteristics define this unique population. Changes in prevention, diagnosis, evaluation, staging, and treatment are needed. This article summarizes the epidemiology and clinical behavior of HPV-associated oropharyngeal cancer and discusses evolving/potential paradigms of treatment. However, data are currently insufficient to change treatment paradigms for HPV-associated oropharyngeal cancer outside of a closely monitored clinical trial.

A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6032-6032 ◽  
Author(s):  
Gregory Michael Cote ◽  
Nicole Grace Chau ◽  
Alexander I. Spira ◽  
William Jeffery Edenfield ◽  
Scott Andrew Laurie ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Disease Control ◽  
Head And Neck ◽  
Neck Cancer ◽  
Kinase Inhibitor ◽  
Head And Neck Cancers ◽  
Advanced Head ◽  
Cancer Stemness ◽  
Anti Cancer ◽  
Cancer Activity

6032 Background: Amcasertib (BBI-503) is an oral first-in-class cancer stemness kinase inhibitor. By targeting multiple serine-threonine stemness kinases, amcasertib inhibits Nanog and other cancer stemness pathways. A phase I clinical trial of amcasertib showed safety and signs of anti-cancer activity in patients (pts) with advanced solid tumors during dose-escalation and RP2D expansion, including pts with advanced head & neck cancer. Methods: Pts with advanced, pre-treated head & neck cancers were enrolled. Amcasertib was administered orally, once or twice daily, in continuous 28-day cycles at a starting dose of 10 mg to 300 mg total daily. Adverse events were categorized according to CTCAE v4.03 and tumor imaging was evaluated per RECIST 1.1 guidelines every 8 weeks. Results: A total of 21 pts were enrolled, 15 with HNSCC and 6 with salivary or parotid gland cancers. Prior treatments included radiation in 90% (19/21), surgery in 71% (15/21) and prior systemic therapy in 90% (19/21, average 3 prior lines, range 1 to 6). Amcasertib was well tolerated with 43% of pts treated at 300 mg daily (n = 9), 33% at 150 mg BID (n = 7), 19% at 200 mg daily (n = 4), and 5% at 10 mg daily (n = 1). Grade 3 AE included diarrhea (n = 4) and nausea (n = 1). Among all patients who received an evaluation per RECIST (n = 16), the objective responses rate (ORR, proportion with partial response [PR] or complete response [CR] per RECIST) was 13% and the disease control rate (DCR, proportion with stable disease [SD] at 8 weeks, PR or CR) was 50%. At 12 months, in the intent-to-treat population (n = 21) 38% of pts were alive. Median overall survival (mOS) of 7.2 months. Conclusions: Clinical safety and encouraging signs of anti-cancer activity were observed in pts with advanced head and neck cancers who have received treatment with amcasertib. Objective response, prolonged disease control, and extended survival have been observed in this pre-treated population with a poor prognosis. Further clinical evaluation of amcasertib in patients with head and neck cancers is warranted. Clinical trial information: NCT01781455.

Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement

2008 ◽  
Vol 87 (2) ◽  
pp. 164-172 ◽  
Author(s):  
Séverine Racadot ◽  
Mariette Mercier ◽  
Sophie Dussart ◽  
Bernadette Dessard-Diana ◽  
René-Jean Bensadoun ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Lymph Node ◽  
Head And Neck ◽  
Randomized Clinical Trial ◽  
Lymph Node Involvement ◽  
Head And Neck Cancers ◽  
Node Involvement
Sign in / Sign up

Export Citation Format

Share Document